181 related articles for article (PubMed ID: 23835526)
1. Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study.
Grohmann R; Engel RR; Möller HJ; Rüther E; van der Velden JW; Stübner S
Eur Arch Psychiatry Clin Neurosci; 2014 Mar; 264(2):131-41. PubMed ID: 23835526
[TBL] [Abstract][Full Text] [Related]
2. Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study.
Gründer G; Heinze M; Cordes J; Mühlbauer B; Juckel G; Schulz C; Rüther E; Timm J;
Lancet Psychiatry; 2016 Aug; 3(8):717-729. PubMed ID: 27265548
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis.
Zhang JP; Gallego JA; Robinson DG; Malhotra AK; Kane JM; Correll CU
Int J Neuropsychopharmacol; 2013 Jul; 16(6):1205-18. PubMed ID: 23199972
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the effectiveness of risperidone, haloperidol and flupentixol long-acting injections in patients with schizophrenia--A nationwide study.
Yu HY; Hsiao CY; Chen KC; Lee LT; Chang WH; Chi MH; Hui Lee I; Chen PS; Yang YK
Schizophr Res; 2015 Dec; 169(1-3):400-405. PubMed ID: 26395153
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms.
Ruhrmann S; Kissling W; Lesch OM; Schmauss M; Seemann U; Philipp M
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1012-22. PubMed ID: 17412473
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Adverse Reactions During Antipsychotic Treatment: Results of AMSP, A Drug Surveillance Program Between 1993 and 2013.
Friedrich ME; Winkler D; Konstantinidis A; Huf W; Engel R; Toto S; Grohmann R; Kasper S
Int J Neuropsychopharmacol; 2020 Feb; 23(2):67-75. PubMed ID: 31504560
[TBL] [Abstract][Full Text] [Related]
7. Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993-2015.
Schneider M; Regente J; Greiner T; Lensky S; Bleich S; Toto S; Grohmann R; Stübner S; Heinze M
Eur Arch Psychiatry Clin Neurosci; 2020 Feb; 270(1):23-33. PubMed ID: 30506147
[TBL] [Abstract][Full Text] [Related]
8. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
9. A meta-analysis of the efficacy of second-generation antipsychotics.
Davis JM; Chen N; Glick ID
Arch Gen Psychiatry; 2003 Jun; 60(6):553-64. PubMed ID: 12796218
[TBL] [Abstract][Full Text] [Related]
10. Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study.
Yang SY; Kao Yang YH; Chong MY; Yang YH; Chang WH; Lai CS
Clin Pharmacol Ther; 2007 Apr; 81(4):586-94. PubMed ID: 17235331
[TBL] [Abstract][Full Text] [Related]
11. Time to Discontinuation of Second-Generation Antipsychotics Versus Haloperidol and Sulpiride in People With Schizophrenia: A Naturalistic, Comparative Study.
Chan HY; Pan YJ; Chen JJ; Chen CH
J Clin Psychopharmacol; 2017 Feb; 37(1):13-20. PubMed ID: 27977467
[TBL] [Abstract][Full Text] [Related]
12. Galactorrhea during antipsychotic treatment: results from AMSP, a drug surveillance program, between 1993 and 2015.
Glocker C; Grohmann R; Engel R; Seifert J; Bleich S; Stübner S; Toto S; Schüle C
Eur Arch Psychiatry Clin Neurosci; 2021 Dec; 271(8):1425-1435. PubMed ID: 33768297
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic drug-induced neutropenia: results from the AMSP drug surveillance program between 1993 and 2016.
Glocker C; Grohmann R; Burkhardt G; Seifert J; Bleich S; Held T; Toto S; Stübner S; Schüle C
J Neural Transm (Vienna); 2023 Feb; 130(2):153-163. PubMed ID: 36653686
[TBL] [Abstract][Full Text] [Related]
14. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Rummel-Kluge C; Komossa K; Schwarz S; Hunger H; Schmid F; Lobos CA; Kissling W; Davis JM; Leucht S
Schizophr Res; 2010 Nov; 123(2-3):225-33. PubMed ID: 20692814
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
[TBL] [Abstract][Full Text] [Related]
16. Atypical dyskinesias under treatment with antipsychotic drugs: Report from the AMSP multicenter drug safety project.
Baumgärtner J; Grohmann R; Bleich S; Glocker C; Seifert J; Toto S; Rüther E; Engel RR; Stübner S
World J Biol Psychiatry; 2022 Feb; 23(2):151-164. PubMed ID: 34096837
[TBL] [Abstract][Full Text] [Related]
17. The expert consensus guideline series. Treatment of behavioral emergencies 2005.
Allen MH; Currier GW; Carpenter D; Ross RW; Docherty JP;
J Psychiatr Pract; 2005 Nov; 11 Suppl 1():5-108; quiz 110-2. PubMed ID: 16319571
[TBL] [Abstract][Full Text] [Related]
18. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.
Naber D; Lambert M
CNS Drugs; 2009 Aug; 23(8):649-59. PubMed ID: 19594194
[TBL] [Abstract][Full Text] [Related]
19. [Comparative effectiveness of flupenthixol and risperidone on negative symptoms of schizophrenia].
Philipp M; Lesch OM; Schmauss M; Dose M; Glaser T
Psychiatr Prax; 2003 May; 30 Suppl 2():S94-6. PubMed ID: 14509050
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with flupentixol results of a post-marketing surveillance study.
Messer T; Glaser T; Landen H; Schmauss M
J Psychopharmacol; 2009 Sep; 23(7):805-13. PubMed ID: 18562418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
